Scholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody Combo

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped patients lose the same amount of weight as patients on tirzepatide alone while preserving more muscle mass.

Scroll to Top